AIA
SPRY icon

AssuredPartners Investment Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

AssuredPartners Investment Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$587K Sell
73,260
-2,950
-4% -$25.4K 0.06% 239
2026
Q1 		$639K Buy
76,210
+431
+0.6% +$4.13K 0.07% 221
2025
Q4 		$883K Buy
75,779
+17,994
+31% +$175K 0.13% 156
2025
Q3 		$581K Buy
57,785
+816
+1% +$11.7K 0.13% 120
2025
Q2 		$994K Sell
56,969
-12,142
-18% -$175K 0.24% 73
2025
Q1 		$869K Buy
69,111
+39,500
+133% +$475K 0.17% 137
2024
Q4 		$312K Buy
+29,611
New +$415K 0.06% 266

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AssuredPartners Investment Advisors's SPRY Position: Q2 2026 in Review

AssuredPartners Investment Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 3.9% in Q2 2026, selling an estimated $25.4K and leaving 73,260 shares worth $587K. The position accounts for 0.06% of the portfolio, ranked #239.

AssuredPartners Investment Advisors first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $994K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • AssuredPartners Investment Advisors held 73,260 shares of ARS Pharmaceuticals worth $587K as of Q2 2026.
  • AssuredPartners Investment Advisors sold 2,950 ARS Pharmaceuticals shares in Q2 2026, an estimated $25.4K.
  • ARS Pharmaceuticals made up 0.06% of AssuredPartners Investment Advisors's portfolio in Q2 2026, its #239 holding.
  • AssuredPartners Investment Advisors first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • AssuredPartners Investment Advisors's ARS Pharmaceuticals position peaked at $994K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on AssuredPartners Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.